Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07284186 · ClinicalTrials.gov registry record · Phase 1

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

A Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor, sponsored by Plexium.

Recruiting
Registry status
Phase 1
Development phase
155
Enrollment target
10
Study locations

NCT07284186: Recruiting Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor, sponsored by Plexium.

NCT07284186 is a Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor that is actively recruiting participants, run by Plexium. The registered enrollment target is 155 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (19% lower). The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07284186, a Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor, is actively recruiting participants, sponsored by Plexium.

RECRUITING
Registry status
Phase 1
Development phase
155 participants
Enrollment target
10
Study locations

Study Summary

A multicenter, single-arm, first-in-human study to investigate the safety, pharmacokinetics, and preliminary antitumor activity of PLX-61639 in participants with locally advanced or metastatic, relapsed/refractory, SMARCA4-deficient solid tumors who are intolerant of or have failed available, approved therapies. The study will be conducted in 3 parts: dose escalation (Part 1), dose optimization (Part 2), and cohort expansion (Part 3). Each part of the study will consist of a Screening Phase lasting up to 28 days during which participants will be assessed for eligibility, a Treatment Phase beginning on Cycle 1 Day 1 and consisting of consecutive 28-day cycles, an End of Treatment Visit, and a Post-Treatment Follow-Up Phase. Participants will receive their assigned dose of PLX-61639 administered orally, once daily until progression/relapse, intolerance, death, or withdrawal from study treatment by the Investigator or participant.

Conditions Studied

Advanced Solid Tumor Metastatic Solid Tumor Gastric Adenocarcinoma Esophageal Adenocarcinoma Non-Small-Cell Lung Carcinoma Esophageal Squamous Cell Carcinoma Gastric Squamous Cell Carcinoma Gastroesophageal Junction (GEJ) Adenocarcinoma SMARCA4 Mutation Gastroesophageal Junction Squamous Cell Carcinoma

Interventions

  • DRUG PLX-61639

Study Locations (10)

California

  • Research Site - Duarte
  • Research Site - Orange

Arizona

  • Research Site - Scottsdale

Massachusetts

  • Research Site - Boston

Missouri

  • Research Site - St Louis

New York

  • Research Site - New York

North Carolina

  • Research Site - Durham

Ohio

  • Research Site - Cleveland

Texas

  • Research Site - San Antonio

Trial Details

FieldValue
Enrollment Target 155 participants
Start Date 2025-12-01
Est. Completion 2030-09
Phase Phase 1
Plexium

1 total trials

What NCT07284186 shows while recruiting

NCT07284186 is an interventional study that assigns participants to a tested intervention. The registered 155 participants enrollment target is mid-sized for trials with a published cap, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (19% lower).

The record links to 10 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which PLX-61639 is the first listed.

NCT07284186 lists 10 locations in 9 states (California, Arizona, Massachusetts).

Frequently Asked Questions

What is clinical trial NCT07284186 about?

NCT07284186 is a clinical study titled "First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors". A multicenter, single-arm, first-in-human study to investigate the safety, pharmacokinetics, and preliminary antitumor activity of PLX-61639 in participants with locally advanced or metastatic, relapsed/refractory, SMARCA4-deficient solid tumors who are intolerant of or have failed available, approv...

What is the current status of trial NCT07284186?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 155 participants. The study started on 2025-12-01. Estimated completion is 2030-09.

What conditions does trial NCT07284186 study?

This clinical trial studies the following conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Non-Small-Cell Lung Carcinoma.

What interventions are being tested in trial NCT07284186?

The interventions under investigation include: PLX-61639 (DRUG).

Who is sponsoring clinical trial NCT07284186?

This trial is sponsored by Plexium, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07284186 being conducted?

This trial has 10 study locations across Arizona, California, Massachusetts, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07284186's enrollment target sits among peer trials

155 83rd of 189 higher than 107 of 189 other Advanced Solid Tumor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03223610 · 155 participants · Phase 1

    Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

  • NCT05072483 · 155 participants

    Natural History Study of CADASIL

  • NCT05086497 · 155 participants · NA

    WBSI Guided Personalized Delivery of TTFields

  • NCT05412069 · 155 participants · NA

    Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07284186

Source: ClinicalTrials.gov NCT07284186, the US trial registry maintained by the National Library of Medicine. NCT07284186 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.